CYDY
$1.50
Cytodyn
CYDY
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Tuesday
Jan 11
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when CYDY reports earnings?
Beat
Meet
Miss

Where is CYDY's stock price going from here?
Up
Flat
Down
Stock chart of CYDY
Analysts
Summary of analysts' recommendations for CYDY
Score
Grade
Pivots
Resistance
$1.60
$1.58
$1.54

$1.52

Support
$1.48
$1.46
$1.42
Tweet
Growth
Description
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.